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Targeting intracellular signaling molecules is an attractiveapproach for treatment of malignancies. On the first day
of the International Association for the Study of Lung Cancer
Winter Meeting, five discussants described progress in this
arena. Four of the talks addressed ongoing work regarding
the role of Src inhibition in upper aerodigestive cancers,
whereas the fifth talk focused on novel approaches to
pathway identification.
SUMMARY OF PRESENTATIONS
Dr. Anne Marie Egloff discussed the role of the epi-
dermal growth factor receptor (EGFR) and Src in lung cancer
and head and neck squamous cell cancer (HNSCC), focusing
on the latter histology. She described commonalities between
the two diseases (tobacco smoking as a risk factor, similar
biology, and approval of EGFR inhibitors).1,2 EGFR is highly
expressed in HNSCC, and expression is directly correlated with
recurrence after primary therapy and inversely correlated with
survival and response to radiation.3 Unlike lung cancer, EGFR
small molecule inhibitors are not approved in HNSCC.
c-Src expression is elevated in many cases of non-small
cell lung cancer (NSCLC) and HNSCC, although mutations
are rare. c-Src modulates signals from surface integrins,
receptor tyrosine kinases, and G-protein-coupled receptors
potentially mediating tumor proliferation and progression.
AZD0530 and dasatinib, both of which are reviewed in detail
by other speakers in the session, were both discussed. Data
demonstrating an IC50 of 30 nM to 2.1 M in HNSCC cell
lines and dose-dependant in vivo efficacy of dasatinib were
shown. Clinical trials of dasatinib with both erlotinib and
cetuximab have been completed. The latter study led to in-
creased serum TGF- and decreased serum EGFR after
treatment (Figure 1). Stable disease in this study was
associated with lower baseline serum TGF- level (Figure
2). Both in vitro and in vivo work demonstrating syner-
gistic efficacy of erlotinib and dasatinib was shown. Dr. Egloff
described a planned “window of opportunity” study in which 56
patients (42 HNSCC and 14 NSCLC) will be randomized to
receive one of four treatments (14 patients each): (1) erlotinib,
(2) dasatinib, (3) erlotinib dasatinib, and (4) placebo for 14 to
21 days before a planned resection. Paired specimens (presur-
gical and surgical specimens) will be obtained from each patient,
and response will be assessed with imaging.
Dr. Eric Haura presented data on the development of
dasatinib in lung cancer. Dasatinib is the only currently Food
and Drug Administration approved Src inhibitor, with approval
in Chronic Myelogenous Leukemia. Dasatinib inhibits Src and
many related tyrosine kinases. Dasatinib is being extensively
studied in lung cancer. In addition to the phase I studies dis-
cussed by Dr. Egloff, phase II evaluation includes studies in
chemonaive NSCLC, patients with acquired resistance to EGFR
tyrosine kinase inhibitors, neoadjuvant therapy in NSCLC and
chemo-sensitive small cell lung cancer. Dr. Haura discussed the
neoadjuvant study in detail. Patients in this study will receive 3
weeks of dasatinib before surgery. Samples before drug expo-
sures will be compared with the surgical specimens. It is hoped
that the study will be able to demonstrate a genomic signature to
assess response.
Dr. Faye Johnson presented data on the c-Src inhibitor
KX2-391, a small molecule that selectively inhibits Src by
binding the substrate binding site, rather than the adenosine
triphosphate (ATP) binding site. KX2-391 was created using
the Mimetica technology platform, created by Dr. David
Hangauer at the University of Buffalo, which generates small
molecules that inhibit the substrate pockets of kinases and
phosphatases. Data were shown in which cell line GI50s
compared favorably to dasatinib, strikingly in some cases.4
All GI50s shown were less than 1 M, including the lung
cancer lines A549, H-226, and H-460. There are two phase I
trials of this compound in progress at this time.
Dr. Primo Lara presented data on the Src inhibitor
AZD0530 in lung cancer. AZD0530 is a potent, selective inhib-
itor of Src family kinases, binding the active conformation of the
ATP binding pocket. The IC50 for c-Src is 2.7 nM, with a
half-life of approximately 40 hours. In comparison with dasta-
tinib, the IC50 for c-Src is slightly higher with a much longer
half-life.5 In an evaluation of several lung cancer cell lines,
AZD0530 decreased p-Src levels in a time and dose-dependant
manner, inhibited cell growth and migration, and increased
apoptosis. Radiation sensitivity was also enhanced in vitro in
response to AZD0530, and this effect was further enhanced by
LY294022, a PI3K-AKT inhibitor.6 AZD0530 has completed
phase I clinical trials and is currently being evaluated in two
phase II trials. One trial enrolls patients with recurrent or pro-
gressive NSCLC after previous treatment with platinum-based
chemotherapy, whereas the other enrolls previously treated pa-
tients with extensive stage small cell lung cancer.
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Dr. Michael Comb described a global phosphopro-
teomic approach to identify protein pathway signaling activ-
ity. The goal of this work is to identify activated kinases and
drivers of disease in individual samples. In doing so, he
proposes that it will be easier to identify patients most likely
to respond to targeted therapies in lung cancer. He stated that
complexity of genomic approaches can be simplified by
focusing on pathways.7 He believes that if a pathway is
activated, the exact event leading to activation is not partic-
ularly relevant. His group is developing “motif” antibodies,
antibodies broadly reactive against different phosphorylated
consensus sequences. Motif sequences can be identified by
cleaving proteins, purifying with “motif” antibodies and eval-
uating with a phosphoscan system.8 This approach was able
to identify not only known pathway drivers (EGFR and ALK
fusions) but also many receptor tyrosine kinases with roles
less clear, including ROS, MET, and PDGF.9
REFERENCES
1. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al.; National Cancer
Institute of Canada Clinical Trials Group. Erlotinib in previously treated
non-small-cell lung cancer. N Engl J Med 2005;353:123–132.
2. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for
squamous-cell carcinoma of the head and neck. N Engl J Med 2006;
354:567–578.
3. Egloff AM, Grandis JR. Targeting epidermal growth factor receptor
and SRC pathways in head and neck cancer. Semin Oncol 2008;35:
286 –297.
4. Lau GM, Lau GM, Yu GL, et al. Expression of Src and FAK in
hepatocellular carcinoma and the effect of Src inhibitors on hepatocel-
lular carcinoma in vitro. Dig Dis Sci 2009;54:1465–1474.
5. Lee D, Gautschi O. Clinical development of SRC tyrosine kinase
inhibitors in lung cancer. Clin Lung Cancer 2006;7:381–384.
6. Purnell PR, Mack PC, Tepper CG, et al. The Src inhibitor AZD0530
blocks invasion and may act as a radiosensitizer in lung cancer cells.
J Thorac Oncol 2009;4:448–454.
7. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human
pancreatic cancers revealed by global genomic analyses. Science 2008;
321:1801–1806.
8. Rush J, Moritz A, Lee KA, et al. Immunoaffinity profiling of tyrosine
phosphorylation in cancer cells. Nat Biotechnol 2005;23:94–101.
9. Guo A, Ville´n J, Kornhauser J, et al. Signaling networks assembled by
oncogenic EGFR and c-Met. Proc Natl Acad Sci USA 2008;105:692–697.
FIGURE 1. Levels of epidermal
growth factor receptor (EGFR) (left)
and Src (right) after therapy on a
phase I clinical trial of cetuximab
and dasatinib are shown at baseline
(25 patients, top panels) and after
15 days (15 patients, bottom
panels).
FIGURE 2. The baseline TGF- level is shown for patients
whose best response was progressive disease (left) or stable
disease (right).
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